Truist Financial Corp Has $29.43 Million Position in IQVIA Holdings Inc. $IQV

Truist Financial Corp reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 154,928 shares of the medical research company’s stock after selling 4,779 shares during the period. Truist Financial Corp owned about 0.09% of IQVIA worth $29,427,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Root Financial Partners LLC bought a new stake in IQVIA during the 3rd quarter worth approximately $43,000. Asset Dedication LLC lifted its holdings in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after purchasing an additional 168 shares during the period. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA in the second quarter worth $39,000. J.Safra Asset Management Corp increased its holdings in IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares during the period. Finally, Hemington Wealth Management raised its position in IQVIA by 43.4% during the 3rd quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock worth $49,000 after purchasing an additional 79 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $235.26 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a market cap of $40.06 billion, a PE ratio of 32.27, a P/E/G ratio of 2.43 and a beta of 1.36. The stock has a 50-day moving average of $230.84 and a 200-day moving average of $207.70. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 earnings per share. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on IQV. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, January 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Barclays set a $230.00 price target on shares of IQVIA in a report on Monday, December 15th. Truist Financial upped their price objective on shares of IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $251.06.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.